Selected ongoing venetoclax combination studies in B-cell lymphomas
| Agent(s) combined with venetoclax . | Phase . | Patients, n . | Patient population . | NCT trial number . | Reference . |
|---|---|---|---|---|---|
| CLL | |||||
| Rituximab | 1b | 49 | R/R | NCT01682616 | 70 |
| Bendamustine plus rituximab or obinutuzumab | 1b | 100* | 1L and R/R | NCT01671904 | 71 |
| Obinutuzumab | 1b | 81 | 1L and R/R | NCT01685892 | 72 |
| Bendamustine → obinutuzumab | 2 | 66 | 1L and R/R | NCT02401503 | 54 |
| Rituximab | 3 | 391 | R/R | NCT02005471 | clinicaltrials.gov |
| Obinutuzumab | 3 | 445 | 1L | NCT02242942 | clinicaltrials.gov |
| Ibrutinib | 2 | 78* | 1L and R/R | NCT02756897 | clinicaltrials.gov |
| Ibrutinib, obinutuzumab | 2 | 40* | 1L del(17p) | NCT02758665 | clinicaltrials.gov |
| Ibrutinib, obinutuzumab | 1b/2 | 68* | 1L and R/R | NCT02427451 | clinicaltrials.gov |
| NHL | |||||
| Rituximab vs bendamustine/rituximab | 2 | 164 | R/R FL | NCT02187861 | 58 |
| Obinutuzumab | 1 | 25* | 1L FL | NCT02877550 | clinicaltrials.gov |
| Ibrutinib | 2 | 24* | 1L MCL | NCT02471391 | 59 |
| R-CHOP or O-CHOP | 1b | 248* | 1L DLBCL | NCT02055820 | 60 |
| Dose-adjusted R-EPOCH | 2 | 20* | Richter syndrome | NCT03054896 | clinicaltrials.gov |
| Agent(s) combined with venetoclax . | Phase . | Patients, n . | Patient population . | NCT trial number . | Reference . |
|---|---|---|---|---|---|
| CLL | |||||
| Rituximab | 1b | 49 | R/R | NCT01682616 | 70 |
| Bendamustine plus rituximab or obinutuzumab | 1b | 100* | 1L and R/R | NCT01671904 | 71 |
| Obinutuzumab | 1b | 81 | 1L and R/R | NCT01685892 | 72 |
| Bendamustine → obinutuzumab | 2 | 66 | 1L and R/R | NCT02401503 | 54 |
| Rituximab | 3 | 391 | R/R | NCT02005471 | clinicaltrials.gov |
| Obinutuzumab | 3 | 445 | 1L | NCT02242942 | clinicaltrials.gov |
| Ibrutinib | 2 | 78* | 1L and R/R | NCT02756897 | clinicaltrials.gov |
| Ibrutinib, obinutuzumab | 2 | 40* | 1L del(17p) | NCT02758665 | clinicaltrials.gov |
| Ibrutinib, obinutuzumab | 1b/2 | 68* | 1L and R/R | NCT02427451 | clinicaltrials.gov |
| NHL | |||||
| Rituximab vs bendamustine/rituximab | 2 | 164 | R/R FL | NCT02187861 | 58 |
| Obinutuzumab | 1 | 25* | 1L FL | NCT02877550 | clinicaltrials.gov |
| Ibrutinib | 2 | 24* | 1L MCL | NCT02471391 | 59 |
| R-CHOP or O-CHOP | 1b | 248* | 1L DLBCL | NCT02055820 | 60 |
| Dose-adjusted R-EPOCH | 2 | 20* | Richter syndrome | NCT03054896 | clinicaltrials.gov |
1L, front line; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin; NCT, National Clinical Trial; O, obinutuzumab; R, rituximab; R/R, relapsed/refractory.
For actively accruing studies, the number listed is the planned total accrual.